ArticleLeukemia2026
CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.
Loélia Babin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleLeukemia2026
Loélia Babin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.